Long-term data from the 48-wk phase 2 SLEek study of upadacitinib +/- a BTK inhibitor elsubrutinib, in SLE pts, showed both arms effective (little added from BTK), @ 1yr, 127 pts maintained efficacy, GC dose and flare rates https://t.co/FbTHCGZ4pQ https://t.co/cATXVHsiXV
Links:
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutini…
https://buff.ly/huEkftY
10-09-2025
